IP Library Granted Patent US 11,970,448
Granted Patent B2
US 11,970,448 · App. 16/929,528 · Granted Apr 30, 2024

Monomers capable of dimerizing in an aqueous solution, and methods of using same

Inventors: Francis Barany (New York, NY); Maneesh Pingle (New York, NY); Donald E. Bergstrom (West Lafayette, IN); Sarah F. Giardina (New York, NY); Lee Daniel Arnold (Mt. Sinai, NY)
Assignees: CORNELL UNIVERSITY; PURDUE RESEARCH FOUNDATION
C07D211/26C07D405/06C07D409/06C07D491/107C07F5/025C07F5/04
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,970,448
App. No.
16/929,528
Granted
Apr 30, 2024
Kind
B2
Abstract

Described herein are monomers capable of forming a biologically useful multimer when in contact with one, two, three or more other monomers in an aqueous media. In one aspect, such monomers may be capable of binding to another monomer in an aqueous media (e.g. in vivo) to form a multimer, (e.g. a dimer). Contemplated monomers may include a ligand moiety, a linker element, and a connector element that joins the ligand moiety and the linker element. In an aqueous media, such contemplated monomers may join together via each linker element and may thus be capable of modulating one or more biomolecules substantially simultaneously, e.g., modulate two or more binding domains on a protein or on different proteins.

Claims (11)

1. A therapeutic composition comprising a first monomer selected from the group consisting of:

and

a second monomer selected from the group consisting of:

and

pharmaceutically acceptable salts, stereoisomers, or hydrates thereof.

2. The therapeutic composition of claim 1 , wherein the first monomer is

and the second monomer is

3. A therapeutic composition comprising a first monomer selected from the group consisting of:

and a second monomer selected from the group consisting of:

and

pharmaceutically acceptable salts, stereoisomers, or hydrates thereof.

Continuity (3)
Continuation 14110056
Provisional Application 61473093 · Apr 7, 2011
Related Publication 20200354319A1 · Nov 12, 2020